A drug that targets the appetite control system in the brain could bring about significant weight loss in people with clinical obesity, according to new research.
The NIH has amended its definition of clinical trials to include brain studies, introducing new regulations considered unnecessary by many researchers.
2nd Gulf Congress of Clinical Microbiology and Infectious Diseases (GCCMID 2017) aims to provide with an enriching scientific and educational gathering in the region.
New research published in the European Heart Journal suggests that blood-thinning drugs such as warfarin may protect not only against stroke, but also against dementia in people who have atrial fibrillation.
Now, in a new study published today in Nature, UNC researchers report a breakthrough. They have used single cell RNA sequencing technology in combination with mathematical modeling and genetic and chemical approaches to delineate the step-by-step molecular changes that occur during cell fate conversion from fibroblast to cardiomyocyte.
AbbVie (ABBV), a global biopharmaceutical company, and Alector, a privately owned biotechnology company, announced a global strategic collaboration to develop and commercialize medicines to treat Alzheimer's disease and other neurodegenerative disorders.
A common thread ties seemingly unlinked disorders like Alzheimer's disease and type II diabetes together. This thread is known as protein aggregation and happens when proteins clump together. These complexes are a hallmark of many diseases, but have recently been linked to beneficial functions as well.
One of the biggest risk factors for vision loss is age. As people grow old, the central part of the retina can become damaged, leading patients to lose the central part of their vision in a condition called age-related macular degeneration (AMD).
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Bydureon® BCise™ (exenatide extended-release) injectable suspension, a new formulation of Bydureon (exenatide extended-release) injectable suspension in an improved once-weekly, single-dose autoinjector device for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines in addition to diet and exercise, to improve glycemic control.
Alexion Pharmaceuticals Inc. is set to secure even more revenue from its blockbuster drug Soliris, the most expensive drug in the world.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.